Effect of Pioglitazone on proteinuria

Evaluating the Effect of Pioglitazone on proteinuria in patients with non diabetic renal disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT138805222340N1

Enrollment

Registered

2010-07-04

Start date

2008-10-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic renal failure. chronic renal failure

Interventions

15 mg of Pioglitasone, dailly for 4 months.

Treatment - Drugs

15 mg of Pioglitasone, dailly for 4 months

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. proteinuria (>500 mg/ day) for at least 6 months; 2. controlled blood pressure for at least 6 months; 3. age more than 18 years; 4. BMI less than 30; 5. serum creatinin less than 6 mg/dl; 6. no diabetes; 7. not using immunosuppressor agents; 8. no heart failure; 9. no liver disease. Exclusion criteria: 1. changes in doses of drugs which have effect on proteinuria (for example ACEI); 2. incidense of complications attributable to the drugs.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Reduction of proteinuria. Timepoint: Every 2 months. Method of measurement: collection of 24-hour urine protein.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Bahram Pakzad

Isfahan Medical School

pakzad@resident.mui.ac.ir+98 31 1568 3840

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026